Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: 10.1007/s00277-023-05394-0
- Ereignis
-
Veröffentlichung
- (wo)
-
Aachen
- (wer)
-
Universitätsbibliothek der RWTH Aachen
- (wann)
-
2023
- Urheber
-
Isfort, Susanne
Manz, Kirsi
Teichmann, Lino L.
Crysandt, Martina
Burchert, Andreas
Hochhaus, Andreas
Saußele, Susanne
Kiani, Alexander
Göthert, Joachim R.
Illmer, Thomas
Schafhausen, Philippe
Al-Ali, Haifa Kathrin
Stegelmann, Frank
Hänel, Mathias
Pfeiffer, Tim
Giagounidis, Aristoteles
Franke, Georg-Nikolaus
Koschmieder, Steffen
Fabarius, Alice
Ernst, Thomas
Warnken-Uhlich, Mareille
Wolber, Uta
Kohn, Denise
Pfirrmann, Markus
Wolf, Dominik
Brümmendorf, Tim Henrik
- Beteiligte Personen und Organisationen
-
German CML study group
- DOI
-
10.18154/RWTH-2023-08981
- URN
-
urn:nbn:de:101:1-2024011200381906943620
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 05:28 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Isfort, Susanne
- Manz, Kirsi
- Teichmann, Lino L.
- Crysandt, Martina
- Burchert, Andreas
- Hochhaus, Andreas
- Saußele, Susanne
- Kiani, Alexander
- Göthert, Joachim R.
- Illmer, Thomas
- Schafhausen, Philippe
- Al-Ali, Haifa Kathrin
- Stegelmann, Frank
- Hänel, Mathias
- Pfeiffer, Tim
- Giagounidis, Aristoteles
- Franke, Georg-Nikolaus
- Koschmieder, Steffen
- Fabarius, Alice
- Ernst, Thomas
- Warnken-Uhlich, Mareille
- Wolber, Uta
- Kohn, Denise
- Pfirrmann, Markus
- Wolf, Dominik
- Brümmendorf, Tim Henrik
- German CML study group
- Universitätsbibliothek der RWTH Aachen
Entstanden
- 2023
Ähnliche Objekte (12)
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
BCAT1 contributes to the development of TKI-resistant CML
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML
TKi | TKi
Is There a Role for Dose Modification of TKI Therapy in CML?
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance
TKI
TKI
TKi
TKi
"TKi"
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
BCAT1 contributes to the development of TKI-resistant CML
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML
TKi | TKi
Is There a Role for Dose Modification of TKI Therapy in CML?
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance
TKI
TKI
TKi
TKi
"TKi"
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
BCAT1 contributes to the development of TKI-resistant CML
Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML
TKi | TKi
Is There a Role for Dose Modification of TKI Therapy in CML?
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance
TKI
TKI
TKi
TKi